BioNTech has finalized an all-stock acquisition of CureVac valued at approximately $1.25 billion, bringing the German mRNA vaccine competitor under its umbrella as a subsidiary. The merger advances BioNTech's oncology strategy by combining complementary mRNA and bispecific antibody pipelines, enhancing cancer immunotherapy efforts. The deal also resolves ongoing patent disputes between the two companies related to COVID-19 vaccine technologies. Integration includes absorption of CureVac's research and manufacturing sites in Germany as BioNTech expands its therapeutic reach.